Lung Cancer
Volume 68, Issue 1 , Pages 84-88 , April 2010

Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer

Received 27 February 2009 ,Revised 7 May 2009 ,Accepted 11 May 2009.

References 

  1. Mountain CF. Revisions in the international staging system for staging lung cancer. Chest. 1997;111:1710–1717
  2. Edelman MJ, Gandara DR, Roach M, Benfield JR. Multimodality therapy in stage III non-small cell lung cancer. Ann Thorac Surg. 1996;61:1564–1572
  3. Rusch VW, Albain KS, Crowley JJ, Rice TW, Lonchyna V, Mekenna R, et al. Surgical resection of stage IIIa and stage IIIb non-small-cell lung cancer after concurrent induction chemoradiotherapy. J Thorac Cardiovasc Surg. 1993;105:96–106
  4. Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol. 2007;25(January (3)):313–318
  5. Albain KS, Swann, Rusch VR, Turrisi AT, Shepherd FA, Smith CJ et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol, 2005 ASCO Annual Meeting Proceedings. 2005;23:16S, Part I of II (June 1 Suppl.), 2005:7014.
  6. Edelman MJ, Suntharalingam M, Burrows W, Kwong KF, Mitra N, Gamliel Z, et al. Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage iii non-small cell lung cancer. Ann Thorac Surg. 2008;86(3):903–910
  7. Sonett J, Suntharalingam M, Edelman MJ, Patel AB, Gamliel Z, Doyle A, et al. Pulmonary resection following neoadjuvant high dose cruative intent radiotherapy (>59GY) and concurrent chemotherapy. Ann Thorac Surg. 2004;78:1200–1205
  8. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S, et al. Paclitaxel sensitivity of breast cancer cells with constituitively active NF-kB is enhanced by IkBa super-repressor and parthenolide. Oncogene. 2000;4159–4169
  9. Russo SM, Tepper JE, Baldwin AS, Liu R, Adams J, Elliott P, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kB. Int J Radiat Oncol Biol Phys. 2001;50:183–193
  10. Denlinger CE, Rundall BK, Keller MD, Jones DR. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg. 2004;4(October (78)):1207–1214
  11. Jung CS, Zhou Z, Khuri FR. Sun SY assessment of apoptosis-inducing effects of docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells. Cancer Biol Ther. 2007;6(May (5)):749–754
  12. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol. 2004;54(October (4)):343–353
  13. Fanucchi MP, Fossella FV, Belt R. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006;24(November (31)):5025–5033
  14. Davies AM, Ruel C, Lara PN, Lau DH, Gumerlock PH, Bold R, et al. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. J Thorac Oncol. 2008;3(January (1)):68–74
  15. Ma C, Mandrekar SJ, Alberts SR. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother Pharmacol. 2007;59(February (2)):207–215
  16. Edelman MJ. The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer. Clin Lung Cancer. 2005;7(October (Suppl. 2)):S64–S66
  17. ATS Board of Directors , ERS Executive Committee . Pretreatment evaluation of non-small cell lung cancer. Am J Respir Crit Care Med. 1997;156:320–332
  18. Furuse K, Fukuoka M, Kawahaa M, Nishikawa H, Takada , Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol. 1999;17(September (9)):2692–2699
  19. Curran WJ, Scott C, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer Initial report of RTOG 9410.. Proc Am Soc Clin Oncol. 2000;19:484a
  20. Martin J, Ginsberg RJ, Abolhoda A, Bains MS, Downey RJ, Korst RJ, et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg. 2001;4(October (72)):1149–1154
  21. Daly BD, Fernando HC, Ketchedjian A, Dipetrillo TA, Kachnic LA, Morelli DM, et al. Pneumonectomy after high-dose radiation and concurrent chemotherapy for nonsmall cell lung cancer. Ann Thorac Surg. 2006;82(July (1)):227–231
  22. Van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer. J Natl Cancer Inst. 2007;99:442–450
  23. Sonett JR, Suntharalingam M, Edelman MJ, Patel AB, Gamliel Z, Doyle A, et al. Induction curative intent radiotherapy (>59GY) and concurrent chemotherapy with surgical resection in locally advanced non-small cell lung cancer: operative feasibility and mid-term survival. Ann Thorac Surg. 2004;78(October (4)):1200–1205[discussion 1206]
  24. Gamliel Z, Burrows W, Sonnett JR, Suntharalingam M, Edelman MJ, Hausner PF, et al. In: Pneumonectomy for lung cancer can be performed safely following preoperative concurrent chemotherapy and high-dose radiation. Presented at the forty-second annual meeting of the society of thoracic surgeons. Chicago, Illinois, January 31, 2006. 2006;Control number: 326
  25. Gotoh A, Ohyashiki K, Oshimi K, Usui N, Hotta T, Dan K, et al. Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the “lung injury by bortezomib” joint committee of the Japanese society of hematology and the Japanese society of clinical hematology. Int J Hematol. 2006;84(December (5)):406–412

☆ Supported by a grant from Millenium Pharmaceuticals.

PII: S0169-5002(09)00267-0

doi: 10.1016/j.lungcan.2009.05.003

Lung Cancer
Volume 68, Issue 1 , Pages 84-88 , April 2010

Article Tools